$CARA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Cara Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Cara Therapeutics, Inc.. Get notifications about new insider transactions in Cara Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 07 2021 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | A | 13.06 | 10,800 | 141,048 | 10,800 | |
Jun 07 2021 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 13.05 | 2,520 | 32,886 | 15,380 | 17.9 K to 15.4 K (-14.08 %) |
Jun 07 2021 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Grant | A | 0.00 | 7,200 | 0 | 17,900 | 10.7 K to 17.9 K (+67.29 %) |
Jun 07 2021 | CARA | Cara Therapeutics, ... | Shiff Susan Ph.D. | Director | Option Exercise | A | 13.06 | 10,800 | 141,048 | 10,800 | |
Jun 07 2021 | CARA | Cara Therapeutics, ... | Shiff Susan Ph.D. | Director | Option Exercise | A | 13.06 | 10,800 | 141,048 | 10,800 | |
Jun 07 2021 | CARA | Cara Therapeutics, ... | Shiff Susan Ph.D. | Director | Grant | A | 0.00 | 7,200 | 0 | 7,200 | 0 to 7.2 K |
Jun 07 2021 | CARA | Cara Therapeutics, ... | Shiff Susan Ph.D. | Director | Grant | A | 0.00 | 7,200 | 0 | 7,200 | 0 to 7.2 K |
Apr 23 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 27.63 | 3,000 | 82,890 | 43,610 | 46.6 K to 43.6 K (-6.44 %) |
Apr 01 2021 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Option Exercise | A | 20.59 | 32,000 | 658,880 | 32,000 | |
Apr 01 2021 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Grant | A | 0.00 | 16,000 | 0 | 67,342 | 51.3 K to 67.3 K (+31.16 %) |
Apr 01 2021 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Option Exercise | A | 20.59 | 32,000 | 658,880 | 32,000 | |
Apr 01 2021 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Grant | A | 0.00 | 16,000 | 0 | 135,319 | 119.3 K to 135.3 K (+13.41 %) |
Apr 01 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Option Exercise | A | 20.59 | 32,000 | 658,880 | 32,000 | |
Apr 01 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Grant | A | 0.00 | 16,000 | 0 | 46,610 | 30.6 K to 46.6 K (+52.27 %) |
Apr 01 2021 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Option Exercise | A | 20.59 | 103,000 | 2,120,770 | 103,000 | |
Apr 01 2021 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Grant | A | 0.00 | 52,000 | 0 | 1,002,511 | 950.5 K to 1 M (+5.47 %) |
Mar 24 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 19.65 | 3,000 | 58,950 | 30,610 | 33.6 K to 30.6 K (-8.93 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 17.98 | 3,358 | 60,377 | 119,319 | 122.7 K to 119.3 K (-2.74 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Grant | A | 0.00 | 10,000 | 0 | 122,677 | 112.7 K to 122.7 K (+8.87 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Sell | S | 17.98 | 3,090 | 55,558 | 51,342 | 54.4 K to 51.3 K (-5.68 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Grant | A | 0.00 | 10,000 | 0 | 54,432 | 44.4 K to 54.4 K (+22.51 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 17.98 | 3,093 | 55,612 | 33,610 | 36.7 K to 33.6 K (-8.43 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Grant | A | 0.00 | 10,000 | 0 | 36,703 | 26.7 K to 36.7 K (+37.45 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 17.98 | 3,103 | 55,792 | 950,511 | 953.6 K to 950.5 K (-0.33 %) |
Mar 08 2021 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Grant | A | 0.00 | 10,000 | 0 | 953,614 | 943.6 K to 953.6 K (+1.06 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Sell | S | 19.33 | 4,004 | 77,397 | 44,432 | 48.4 K to 44.4 K (-8.27 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Grant | A | 0.00 | 6,000 | 0 | 48,436 | 42.4 K to 48.4 K (+14.14 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 19.33 | 5,003 | 96,708 | 112,677 | 117.7 K to 112.7 K (-4.25 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Grant | A | 0.00 | 8,000 | 0 | 117,680 | 109.7 K to 117.7 K (+7.29 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 19.33 | 3,372 | 65,181 | 26,703 | 30.1 K to 26.7 K (-11.21 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Grant | A | 0.00 | 4,000 | 0 | 30,075 | 26.1 K to 30.1 K (+15.34 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 19.33 | 11,729 | 226,722 | 943,614 | 955.3 K to 943.6 K (-1.23 %) |
Feb 25 2021 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Grant | A | 0.00 | 18,750 | 0 | 955,343 | 936.6 K to 955.3 K (+2.00 %) |
Feb 24 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 19.73 | 2,000 | 39,460 | 26,075 | 28.1 K to 26.1 K (-7.12 %) |
Jan 25 2021 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 20.12 | 2,000 | 40,240 | 28,075 | 30.1 K to 28.1 K (-6.65 %) |
Dec 30 2020 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Sell | S | 15.30 | 1,946 | 29,774 | 42,436 | 44.4 K to 42.4 K (-4.38 %) |
Dec 30 2020 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 15.30 | 2,812 | 43,024 | 109,680 | 112.5 K to 109.7 K (-2.50 %) |
Dec 30 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 15.30 | 1,298 | 19,859 | 30,075 | 31.4 K to 30.1 K (-4.14 %) |
Dec 30 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 15.30 | 6,078 | 92,993 | 936,593 | 942.7 K to 936.6 K (-0.64 %) |
Dec 29 2020 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Grant | A | 0.00 | 8,000 | 0 | 112,492 | 104.5 K to 112.5 K (+7.66 %) |
Dec 29 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Grant | A | 0.00 | 4,000 | 0 | 31,373 | 27.4 K to 31.4 K (+14.61 %) |
Dec 29 2020 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Grant | A | 0.00 | 6,000 | 0 | 44,382 | 38.4 K to 44.4 K (+15.63 %) |
Dec 29 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 5,000 | 80,000 | 942,671 | 947.7 K to 942.7 K (-0.53 %) |
Dec 29 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Grant | A | 0.00 | 18,750 | 0 | 947,671 | 928.9 K to 947.7 K (+2.02 %) |
Dec 23 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 15.00 | 2,000 | 30,000 | 27,373 | 29.4 K to 27.4 K (-6.81 %) |
Dec 18 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 14.95 | 5,000 | 74,750 | 928,921 | 933.9 K to 928.9 K (-0.54 %) |
Dec 11 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 15.29 | 7,500 | 114,675 | 933,921 | 941.4 K to 933.9 K (-0.80 %) |
Nov 25 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 15.31 | 2,000 | 30,620 | 29,373 | 31.4 K to 29.4 K (-6.37 %) |
Nov 25 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 15.31 | 2,000 | 30,620 | 29,373 | 31.4 K to 29.4 K (-6.37 %) |
Nov 23 2020 | CARA | Cara Therapeutics, ... | Posner Christopher | Director | Sell | S | 15.82 | 2,000 | 31,638 | 11,200 | 13.2 K to 11.2 K (-15.15 %) |
Nov 23 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Grant | A | 15.75 | 2,500 | 39,373 | 10,700 | 8.2 K to 10.7 K (+30.49 %) |
Nov 19 2020 | CARA | Cara Therapeutics, ... | VOGELBAUM MARTIN | Director | Sell | S | 16.09 | 6,000 | 96,540 | 14,400 | 20.4 K to 14.4 K (-29.41 %) |
Nov 19 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 11,799 | 188,784 | 941,421 | 953.2 K to 941.4 K (-1.24 %) |
Nov 13 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 15.00 | 2,000 | 30,000 | 31,373 | 33.4 K to 31.4 K (-5.99 %) |
Oct 22 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 15.00 | 2,000 | 30,000 | 33,373 | 35.4 K to 33.4 K (-5.65 %) |
Oct 07 2020 | CARA | Cara Therapeutics, ... | Reilly Thomas Charles | Chief Financial Off ... | Option Exercise | A | 12.74 | 175,000 | 2,229,500 | 175,000 | |
Oct 07 2020 | CARA | Cara Therapeutics, ... | Reilly Thomas Charles | Chief Financial Off ... | Option Exercise | A | 12.74 | 175,000 | 2,229,500 | 175,000 | |
Sep 08 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 3,201 | 51,216 | 953,220 | 956.4 K to 953.2 K (-0.33 %) |
Aug 05 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.42 | 5,000 | 82,100 | 956,421 | 961.4 K to 956.4 K (-0.52 %) |
Jun 30 2020 | CARA | Cara Therapeutics, ... | Shiff Susan Ph.D. | Director | Option Exercise | A | 17.03 | 38,000 | 647,140 | 38,000 | |
Jun 30 2020 | CARA | Cara Therapeutics, ... | Shiff Susan Ph.D. | Director | Option Exercise | A | 17.03 | 38,000 | 647,140 | 38,000 | |
Jun 12 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Sell | S | 15.20 | 10,627 | 161,530 | 35,373 | 46 K to 35.4 K (-23.10 %) |
Jun 12 2020 | CARA | Cara Therapeutics, ... | Goncalves Joana | Chief Medical Offic ... | Grant | A | 0.00 | 30,000 | 0 | 46,000 | 16 K to 46 K (+187.50 %) |
Jun 08 2020 | CARA | Cara Therapeutics, ... | VOGELBAUM MARTIN | Director | Option Exercise | A | 15.62 | 21,600 | 337,392 | 21,600 | |
Jun 08 2020 | CARA | Cara Therapeutics, ... | VOGELBAUM MARTIN | Director | Grant | A | 0.00 | 14,400 | 0 | 20,400 | 6 K to 20.4 K (+240.00 %) |
Jun 08 2020 | CARA | Cara Therapeutics, ... | BAINS HARRISON M JR | Director | Option Exercise | A | 15.62 | 10,800 | 168,696 | 10,800 | |
Jun 08 2020 | CARA | Cara Therapeutics, ... | BAINS HARRISON M JR | Director | Grant | A | 0.00 | 7,200 | 0 | 13,200 | 6 K to 13.2 K (+120.00 %) |
Jun 08 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | A | 15.62 | 10,800 | 168,696 | 10,800 | |
Jun 08 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Grant | A | 0.00 | 7,200 | 0 | 13,200 | 6 K to 13.2 K (+120.00 %) |
Jun 08 2020 | CARA | Cara Therapeutics, ... | Posner Christopher | Director | Option Exercise | A | 15.62 | 10,800 | 168,696 | 10,800 | |
Jun 08 2020 | CARA | Cara Therapeutics, ... | Posner Christopher | Director | Grant | A | 0.00 | 7,200 | 0 | 13,200 | 6 K to 13.2 K (+120.00 %) |
Jun 03 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.01 | 4,300 | 68,843 | 966,421 | 970.7 K to 966.4 K (-0.44 %) |
Jun 03 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 700 | 11,200 | 970,721 | 971.4 K to 970.7 K (-0.07 %) |
Jun 03 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 9.94 | 1,000 | 9,940 | 0 | |
Jun 03 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 16.00 | 1,000 | 16,000 | 6,000 | 7 K to 6 K (-14.29 %) |
Jun 03 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 9.94 | 1,000 | 9,940 | 7,000 | 6 K to 7 K (+16.67 %) |
May 22 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 371 | 5,936 | 971,421 | 971.8 K to 971.4 K (-0.04 %) |
May 22 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 3,500 | 56,000 | 971,792 | 975.3 K to 971.8 K (-0.36 %) |
May 22 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 1,200 | 19,200 | 975,292 | 976.5 K to 975.3 K (-0.12 %) |
May 14 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.00 | 4,929 | 78,864 | 976,492 | 981.4 K to 976.5 K (-0.50 %) |
May 14 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 9.94 | 2,500 | 24,850 | 1,000 | |
May 14 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 16.00 | 2,500 | 40,000 | 6,000 | 8.5 K to 6 K (-29.41 %) |
May 14 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 9.94 | 2,500 | 24,850 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 9.94 | 2,500 | 24,850 | 3,500 | |
Apr 21 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 16.00 | 2,500 | 40,000 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 9.94 | 2,500 | 24,850 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Sell | S | 15.56 | 2,721 | 42,339 | 38,382 | 41.1 K to 38.4 K (-6.62 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Grant | A | 0.00 | 8,334 | 0 | 41,103 | 32.8 K to 41.1 K (+25.43 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 15.58 | 12,894 | 200,889 | 104,492 | 117.4 K to 104.5 K (-10.98 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Grant | A | 0.00 | 37,500 | 0 | 117,386 | 79.9 K to 117.4 K (+46.94 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 15.56 | 6,348 | 98,775 | 981,421 | 987.8 K to 981.4 K (-0.64 %) |
Apr 21 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Grant | A | 0.00 | 20,000 | 0 | 987,769 | 967.8 K to 987.8 K (+2.07 %) |
Mar 06 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 9.94 | 2,500 | 24,850 | 6,000 | |
Mar 06 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 16.00 | 2,500 | 40,000 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Mar 06 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 9.94 | 2,500 | 24,850 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Feb 26 2020 | CARA | Cara Therapeutics, ... | Makara Richard | VP, Head of Accting ... | Option Exercise | A | 16.36 | 30,000 | 490,800 | 30,000 | |
Feb 26 2020 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Option Exercise | A | 16.36 | 32,000 | 523,520 | 32,000 | |
Feb 26 2020 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Grant | A | 0.00 | 16,000 | 0 | 32,769 | 16.8 K to 32.8 K (+95.41 %) |
Feb 26 2020 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Option Exercise | A | 16.36 | 32,000 | 523,520 | 32,000 | |
Feb 26 2020 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Grant | A | 0.00 | 16,000 | 0 | 79,886 | 63.9 K to 79.9 K (+25.04 %) |
Feb 26 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Option Exercise | A | 16.36 | 100,000 | 1,636,000 | 100,000 | |
Feb 26 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Grant | A | 0.00 | 50,000 | 0 | 967,769 | 917.8 K to 967.8 K (+5.45 %) |
Feb 05 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 9.94 | 2,500 | 24,850 | 8,500 | |
Feb 05 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 16.23 | 2,500 | 40,575 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Feb 05 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 9.94 | 2,500 | 24,850 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Jan 06 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 9.94 | 2,500 | 24,850 | 11,000 | |
Jan 06 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 16.13 | 2,500 | 40,325 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Jan 06 2020 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 9.94 | 2,500 | 24,850 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Jan 06 2020 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 16.05 | 10,000 | 160,500 | 917,769 | 927.8 K to 917.8 K (-1.08 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Sell | S | 17.05 | 3,980 | 67,859 | 16,769 | 20.7 K to 16.8 K (-19.18 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | Terrillion Scott | Sec'y; Chief Compli ... | Grant | A | 0.00 | 8,333 | 0 | 20,749 | 12.4 K to 20.7 K (+67.12 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | Mohindru Mani | CFO & Chief Strateg ... | Sell | S | 17.05 | 4,755 | 81,073 | 17,441 | 22.2 K to 17.4 K (-21.42 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | Mohindru Mani | CFO & Chief Strateg ... | Grant | A | 0.00 | 8,333 | 0 | 22,196 | 13.9 K to 22.2 K (+60.11 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 5.32 | 2,500 | 13,300 | 0 | |
Dec 04 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 25.83 | 2,500 | 64,575 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 5.32 | 2,500 | 13,300 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 17.05 | 10,699 | 182,418 | 927,769 | 938.5 K to 927.8 K (-1.14 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Grant | A | 0.00 | 20,000 | 0 | 938,468 | 918.5 K to 938.5 K (+2.18 %) |
Dec 04 2019 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 25.79 | 10,000 | 257,900 | 918,468 | 928.5 K to 918.5 K (-1.08 %) |
Nov 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 5.32 | 2,500 | 13,300 | 2,500 | |
Nov 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 20.68 | 2,500 | 51,700 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Nov 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 5.32 | 2,500 | 13,300 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Nov 05 2019 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 20.79 | 5,000 | 103,950 | 928,468 | 933.5 K to 928.5 K (-0.54 %) |
Oct 29 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 19.91 | 4,000 | 79,640 | 63,886 | 67.9 K to 63.9 K (-5.89 %) |
Oct 22 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 19.33 | 4,000 | 77,320 | 67,886 | 71.9 K to 67.9 K (-5.56 %) |
Oct 16 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 18.70 | 4,000 | 74,800 | 71,886 | 75.9 K to 71.9 K (-5.27 %) |
Oct 08 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 19.19 | 4,000 | 76,760 | 75,886 | 79.9 K to 75.9 K (-5.01 %) |
Oct 03 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 5.32 | 2,500 | 13,300 | 5,000 | |
Oct 03 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 18.21 | 2,500 | 45,525 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Oct 03 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 5.32 | 2,500 | 13,300 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Oct 03 2019 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 18.28 | 10,000 | 182,800 | 933,468 | 943.5 K to 933.5 K (-1.06 %) |
Sep 05 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 22.92 | 20,000 | 458,400 | 79,886 | 99.9 K to 79.9 K (-20.02 %) |
Sep 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 5.32 | 2,500 | 13,300 | 7,500 | |
Sep 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 23.31 | 2,500 | 58,275 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Sep 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 5.32 | 2,500 | 13,300 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Sep 05 2019 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 23.26 | 5,000 | 116,300 | 943,468 | 948.5 K to 943.5 K (-0.53 %) |
Aug 05 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 23.24 | 20,000 | 464,800 | 99,886 | 119.9 K to 99.9 K (-16.68 %) |
Aug 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Option Exercise | M | 5.32 | 2,500 | 13,300 | 10,000 | |
Aug 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Sell | S | 23.24 | 2,500 | 58,100 | 6,000 | 8.5 K to 6 K (-29.41 %) |
Aug 05 2019 | CARA | Cara Therapeutics, ... | Ives Jeffrey L. | Director | Buy | M | 5.32 | 2,500 | 13,300 | 8,500 | 6 K to 8.5 K (+41.67 %) |
Aug 05 2019 | CARA | Cara Therapeutics, ... | CHALMERS DEREK T | President & CEO | Sell | S | 23.27 | 10,000 | 232,700 | 948,468 | 958.5 K to 948.5 K (-1.04 %) |
Jul 19 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 27.50 | 8,996 | 247,390 | 119,886 | 128.9 K to 119.9 K (-6.98 %) |
Jul 17 2019 | CARA | Cara Therapeutics, ... | Mohindru Mani | CFO & Chief Strateg ... | Option Exercise | M | 14.06 | 37,431 | 526,280 | 299,444 | |
Jul 17 2019 | CARA | Cara Therapeutics, ... | Mohindru Mani | CFO & Chief Strateg ... | Sell | S | 25.00 | 37,431 | 935,775 | 13,863 | 51.3 K to 13.9 K (-72.97 %) |
Jul 17 2019 | CARA | Cara Therapeutics, ... | Mohindru Mani | CFO & Chief Strateg ... | Buy | M | 14.06 | 37,431 | 526,280 | 51,294 | 13.9 K to 51.3 K (+270.01 %) |
Jul 03 2019 | CARA | Cara Therapeutics, ... | Menzaghi Frederique Ph.D. | Chief Scientific Of ... | Sell | S | 21.90 | 20,000 | 438,000 | 128,882 | 148.9 K to 128.9 K (-13.43 %) |
Jun 06 2019 | CARA | Cara Therapeutics, ... | VOGELBAUM MARTIN | Director | Option Exercise | A | 20.44 | 9,000 | 183,960 | 9,000 | |
Jun 06 2019 | CARA | Cara Therapeutics, ... | VOGELBAUM MARTIN | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
Jun 06 2019 | CARA | Cara Therapeutics, ... | Posner Christopher | Director | Option Exercise | A | 20.44 | 9,000 | 183,960 | 9,000 | |
Jun 06 2019 | CARA | Cara Therapeutics, ... | Posner Christopher | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |